share_log

Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Maxim Group 將Galmed Pharmicals升級爲收購,宣佈目標股價爲4美元
Benzinga ·  2023/07/24 08:57

Maxim Group analyst Jason McCarthy upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and announces $4 price target.

Maxim集團分析師傑森·麥卡錫將Galmed Pharmicals(納斯達克股票代碼:GLMD)從持有上調至買入,並宣佈目標股價爲4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論